Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients

Clinical Pharmacokinetics

Volumn 47, Issue 11, 2008, Pages 733-742

  Mendonza, Anisha E ^a   Gohh, Reginald Y ^b   Akhlaghi, Fatemeh ^a,c  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Ciclosporin, pharmacokinetics; Diabetes mellitus; Immunosuppressants, pharmacokinetics; Paracetamol, pharmacokinetics; Renal transplant

Indexed keywords

CONCENTRATED TYLENOL INFANT DROPS; CYCLOSPORIN A; INSULIN; LONG ACTING INSULIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PARACETAMOL; PREDNISONE; SHORT ACTING DRUG; TRITIUM; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MALE; PARAMETER; PHARMACOKINETICS; PRIORITY JOURNAL; RECIPIENT; STEADY STATE; STOMACH EMPTYING; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

CYCLOSPORINE; DIABETIC NEPHROPATHIES; FEMALE; GASTRIC EMPTYING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 53549130008     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847110-00004     Document Type: Article

References (42)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351 (26): 2715-29
2. Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Ther Drug Monit 2006; 28 (6): 720-5
3. Akhlaghi F, Trull AK. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 2002; 41 (9): 615-37
4. Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®) in organ transplantation. Drugs 2001; 61 (13): 1957-2016
5. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18 (5): 595-606
6. Wadhwa NK, Schroeder TJ, Pesce AJ, et al. Cyclosporine drug interactions: a review. Ther Drug Monit 1987; 9 (4): 399-406
7. Nankivell BJ, Hibbins M, Chapman JR. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 1994; 58 (9): 989-96
8. Oellerich M, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther Drug Monit 2002; 24 (1): 40-6
9. Rowland M. Plasma protein binding and therapeutic drug monitoring. Ther Drug Monit 1980; 2 (1): 29-37
10. Levy RH, Moreland TA. Rationale for monitoring free drug levels. Clin Pharmacokinet 1984; 9 Suppl. 1: 1-9
11. Lindholm A. Monitoring of the free concentration of cyclosporine in plasma in man. Eur J Clin Pharmacol 1991; 40 (6): 571-5
12. Akhlaghi F, Keogh AM, Brown KF. Unbound cyclosporine and allograft rejection after heart transplantation. Transplantation 1999; 67: 54-9
13. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991; 20 (6): 477-90
14. US Centers for Disease Control and Prevention. Incidence of end-stage renal disease among persons with diabetes: United States, 1990-2002. MMWR Morb Mortal Wkly Rep 2005; 54: 1097-100
15. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-85
16. Cashion AK, Holmes SL, Hathaway DK, et al. Gastroparesis following kidney/pancreas transplant. Clin Transplant 2004; 18 (3): 306-11
17. Zini R, Riant P, Barre J, et al. Disease-induced variations in plasma protein levels: implications for drug dosage regimens (part I). Clin Pharmacokinet 1990; 19 (2): 147-59
18. Okabe N, Hashizume N. Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism. Biol Pharm Bull 1994; 17: 16-21
19. Cheng PY, Morgan ET. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2001; 2: 165-83
20. Morgan ET, Sewer MB, Iber H, et al. Physiological and pathophysiological regulation of cytochrome P450. Drug Metab Dispos 1998; 26: 1232-40
21. D'Souza MJ, Solomon HM, Fowler LC, et al. Pharmacokinetics of cyclosporine in streptozotocin-induced diabetic rats. Drug Metab Dispos 1988; 16 (5): 778-80
22. Wijkstrom M, Kirchhof N, Graham M, et al. Cyclosporine toxicity in immunosuppressed streptozotocin-diabetic nonhuman primates. Toxicology 2005; 207 (1): 117-27
23. Wadhawan S, Jauhari H, Singh S. Cyclosporine trough levels in diabetic and nondiabetic renal transplant patients. Transplant Proc 2000; 32 (7): 1683-4
24. van der Pijl JW, Srivastava N, Denouel J, et al. Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis. Transplantation 1996; 62 (4): 456-62
25. Roza A, Tomlanovich S, Merion R, et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation 2002; 74: 1013-7
26. Agarwal RP, Threatte GA, McPherson RA. Temperature-dependent binding of cyclosporine to an erythrocyte protein. Clin Chem 1987; 33: 481-5
27. Akhlaghi F, Patel CG, Zuniga XP, et al. Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit 2006; 28 (1): 95-101
28. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm Res 2000; 17: 1551-7
29. Mendonza AE, Gohh RY, Akhlaghi F. Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry. Ther Drug Monit 2006; 28 (3): 402-6
30. Akhlaghi F, McLachlan AJ, Keogh AM, et al. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 1997; 44 (6): 537-42
31. Akhlaghi F, Keogh AM, McLachlan AJ, et al. Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant 2001; 20 (4): 431-8
32. Koch KL. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus. A review of symptoms, pathophysiology, and treatment. Dig Dis Sci 1999; 44 (6): 1061-75
33. Sanaka M, Koike Y, Yamamoto T, et al. A reliable and convenient parameter of the rate of paracetamol absorption to measure gastric emptying rate of liquids. Int J Clin Pharmacol Ther 1997; 35 (11): 509-13
34. Kelly K, O'Mahony B, Lindsay B, et al. Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy. Pharm Res 2003; 20 (10): 1668-73
35. Patel CG, Richman K, Yang D, et al. Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. Ther Drug Monit 2007; 29 (6): 735-42
36. Mendonza AE, Zahir H, Gohh RY, et al. Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2007; 29 (4): 391-8
37. Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 1982; 34 (11): 715-8
38. Gurecki J, Warty V, Sanghvi A. The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients. Transplant Proc 1985; 17 (4): 1997-2002
39. Rowland M. Protein binding and drug clearance. Clin Pharmacokinet 1984; 9 Suppl. 1: 10-7
40. Wang T, Fontenot RD, Soni MG, et al. Enhanced hepatotoxicity and toxic outcome of thioacetamide in streptozotocin-induced diabetic rats. Toxicol Appl Pharmacol 2000; 166 (2): 92-100
41. Watkins III JB, Sherman SE. Long-term diabetes alters the hepatobiliary clearance of acetaminophen, bilirubin and digoxin. J Pharmacol Exp Ther 1992; 260 (3): 1337-43
42. Shankar K, Vaidya VS, Apte UM, et al. Type 1 diabetic mice are protected from acetaminophen hepatotoxicity. Toxicol Sci 2003; 73 (2): 220-34